4//SEC Filing
Aimmune Therapeutics, Inc. 4
Accession 0000899243-16-014622
CIK 0001631650operating
Filed
Feb 25, 7:00 PM ET
Accepted
Feb 26, 7:43 PM ET
Size
7.6 KB
Accession
0000899243-16-014622
Insider Transaction Report
Form 4
Knapp Jeffrey H
Chief Operating Officer
Transactions
- Award
Common Stock, $0.0001 par value
2016-02-26+5,000→ 5,000 total - Award
Stock Option (right to buy)
2016-02-26+250,000→ 250,000 totalExercise: $16.93Exp: 2026-02-26→ Common Stock (250,000 underlying)
Footnotes (2)
- [F1]These shares represent restricted stock units ("RSUs") and will be settled in common stock upon vesting. The RSUs vest in full on February 1, 2017.
- [F2]The shares subject to the option will vest and become exercisable as to 25% of the total number of shares subject to the option on February 1, 2017 and with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the Reporting Person's continued service relationship with the Issuer on each such vesting date.
Documents
Issuer
Aimmune Therapeutics, Inc.
CIK 0001631650
Entity typeoperating
IncorporatedDE
Related Parties
1- filerCIK 0001631650
Filing Metadata
- Form type
- 4
- Filed
- Feb 25, 7:00 PM ET
- Accepted
- Feb 26, 7:43 PM ET
- Size
- 7.6 KB